[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355473-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355473-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plantaricin-bm-1-enhances-anticolorectal-cancer-effects-by-inhibiting-cd8-cytotoxic-t-cell-apoptosis-via-the-erkap1bim-signaling-pathway","Plantaricin BM-1 enhances anticolorectal cancer effects by inhibiting CD8+ cytotoxic T cell apoptosis via the ERK/AP1/Bim signaling pathway","","Colorectal cancer remains a major cause of cancer-related mortality, and in vivo efficacy of the class IIa bacteriocin Plantaricin BM-1 against CRC is unclear. An AOM/DSS-induced mouse model was used to administer Plantaricin BM-1 orally and assess therapeutic outcomes through phenotypic, pathological, and inflammatory measurements. scRNA-seq defined molecular mechanisms and was validated by RT-qPCR, IHC, flow cytometry, and Western blot. Plantaricin BM-1 suppressed tumorigenesis, reduced colon shortening and TNF-α, increased tumor-infiltrating T cells, expanded cytotoxic CD8+ T cells, upregulated key cytotoxic genes, inhibited the ERK/AP1 pathway, and blocked CD8+ T cell apoptosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plantaricin-bm-1-enhances-anticolorectal-cancer-effects-by-inhibiting-cd8-cytotoxic-t-cell-apoptosis-via-the-erkap1bim-signaling-pathway/355473/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plantaricin-bm-1-enhances-anticolorectal-cancer-effects-by-inhibiting-cd8-cytotoxic-t-cell-apoptosis-via-the-erkap1bim-signaling-pathway/355473.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic hypothesis tested for Plantaricin BM-1 in colorectal cancer?","Question",{"text":63,"@type":64},"Plantaricin BM-1 is proposed to enhance anti-CRC effects by inhibiting apoptosis of CD8+ cytotoxic T cells through the ERK/AP1/Bim signaling pathway.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the colorectal cancer model designed and how was treatment delivered?",{"text":68,"@type":64},"An AOM/DSS-induced CRC mouse model was used, and Plantaricin BM-1 was administered orally for therapeutic evaluation.",{"name":70,"@type":61,"acceptedAnswer":71},"Which methods were used to evaluate efficacy and uncover mechanisms?",{"text":72,"@type":64},"Efficacy was assessed using phenotypic, pathological, and inflammatory assessments, while mechanisms were studied with scRNA-seq and validated by RT-qPCR, IHC, flow cytometry, and Western blot.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355473,1790141990,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Original Research PUBLISHED 30 March 2026  \nDOI 10.3389/fimmu.2026.1792962  \nOPEN ACCESS  \nEDITED BY  \nXuefeng Wang,  \nSoochow University, China  \nREVIEWED BY  \nLiang-min Fu,  \nThe First Afﬁliated Hospital of Sun Yat-sen University, China  \nKe Nan,  \nFudan University, China  \n*CORRESPONDENCE  \nHongxing Zhang  \n [hxzhang511@163.com](hxzhang511@163.com)[ ](hxzhang511@163.com)Yuanhong Xie  \n[xieyuanh@163.com](xieyuanh@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 21 January 2026  \nREVISED 03 March 2026  \nACCEPTED 09 March 2026  \nPUBLISHED 30 March 2026  \nCITATION  \nZheng X, Wang Q, Song X, Zhu J, Dai C, Jin J, Cheng C, Zhang H and Xie Y (2026) Plantaricin BM-1 enhances anticolorectal cancer effects by inhibiting CD8+ cytotoxic T cell apoptosis via the ERK/AP1/Bim signaling pathway.  \nFront. Immunol. 17:1792962 .  \ndoi: 10.3389/fimmu.2026.1792962  \nCOPYRIGHT  \n© 2026 Zheng, Wang, Song, Zhu, Dai, Jin, Cheng, Zhang and Xie. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPlantaricin BM-1 enhances anticolorectal cancer effects by inhibiting CD8+ cytotoxic T cell apoptosis via the ERK/AP1/ Bim signaling pathway  \nXuan Zheng 1†, Qi Wang 1†, Xiaodong Song 2, Jingxin Zhu 1, Chunyu Dai 1, Junhua Jin 1, Congyang Cheng 2, Hongxing Zhang 1* and Yuanhong Xie 1*  \n1 Beijing Laboratory of Food Quality and Safety, Beijing Key Laboratory of Agricultural Product Detection and Control of Spoilage Organisms and Pesticide Residue, College of Food Science and Engineering, Beijing University of Agriculture, Beijing, China, 2 Key Laboratory of Dairy Quality Digital Intelligence Monitoring Technology, State Administration for Market Regulation, Inner Mongolia Mengniu Dairy (Group) Co., Ltd., Hohhot, Inner Mongolia, China  \nIntroduction: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality. Plantaricin BM-1, a class IIa bacteriocin from Lactobacillus plantarum, exhibits anticancer potential, but its in vivo efﬁcacy against CRC is unclear. Methods: Using an AOM/DSS-induced CRC mouse model, we administered Plantaricin BM-1 orally and evaluated therapeutic effects via phenotypic, pathological, and inﬂammatory assessments. scRNA-seq elucidated molecular mechanisms, validated by RT-qPCR, IHC, ﬂow cytometry, and Western blot. Discussion: ResultsResults demonstrated that Plantaricin BM-1 signiﬁcantly suppressed tumorigenesis, colon shortening, serum TNF-a levels, and pathological damage. sc RNA-seq revealed a 17 . 38% increase in tumorinﬁltrating T cells and a 9 . 29% expansion of cytotoxic CD8⁺ T cells. Key cytotoxic genes (Gzma, Gzmb, Fasl) were upregulated in CD8⁺ T cells, while the ERK/AP1 pathway was suppressed. Consistently, Plantaricin BM-1 downregulated ERK, AP1, and pro-apoptotic Bim in vivo and in vitro. Crucially, it inhibited CD8⁺ T cell apoptosis via the ERK/AP1 pathway.  \nDiscussion: These ﬁndings provide mechanistic insights for developing Plantaricin BM-1 as an anti-CRC agent.  \nKEYWORDS  \napoptosis, colorectal cancer, cytotoxic CD8+ T cells, plantaricin BM-1, scRNA-seq  \n1 Introduction  \nColorectal cancer (CRC), which includes both colon and rectal cancers, is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related deaths (1) . Globally, the incidence of CRC cases is increasing, with more than 1.9 million new cases and over 900,000 deaths reported in 2020 (2) . By 2040, the number ofCRC cases and CRC-related deaths is projected to reach 3.2 million and 1.6 million, respectively (3) . Based on its pathogenesis, CRC can be classiﬁed into sporadic, heredit","cbCaiom6aWV6r1RK","https://ap.wps.com/l/cbCaiom6aWV6r1RK","pdf",10210932,18,"English","# Introduction\n## Colorectal cancer background and current treatments\n## Rationale for bacteriocins and Plantaricin BM-1","[{\"question\":\"What is the main therapeutic hypothesis tested for Plantaricin BM-1 in colorectal cancer?\",\"answer\":\"Plantaricin BM-1 is proposed to enhance anti-CRC effects by inhibiting apoptosis of CD8+ cytotoxic T cells through the ERK/AP1/Bim signaling pathway.\"},{\"question\":\"How was the colorectal cancer model designed and how was treatment delivered?\",\"answer\":\"An AOM/DSS-induced CRC mouse model was used, and Plantaricin BM-1 was administered orally for therapeutic evaluation.\"},{\"question\":\"Which methods were used to evaluate efficacy and uncover mechanisms?\",\"answer\":\"Efficacy was assessed using phenotypic, pathological, and inflammatory assessments, while mechanisms were studied with scRNA-seq and validated by RT-qPCR, IHC, flow cytometry, and Western blot.\"}]","Plantaricin BM-1 enhances anticolorectal cancer effects by inhibiting CD8+ cytotoxic T cell apoptosis via the ERK/AP1/Bim signaling pathway | PDF",1790119187,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f94200784c47dfba9f2f6db89d0c573.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e34e5402afd74b42ee443d830e1ab832.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faa63747eada49cb332d38ad838d0758.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c0b2339721a198a8d216dab788de210.webp",980,1385]